Quell Therapeutics’ Post

We are pleased to welcome Luke Beshar as Chair of Quell’s Board of Directors.   Luke brings more than 35 years of strategic development, financial and transactional experience to Quell from his Board and C- suite executive roles at several innovative, high-growth public and private companies. This experience will be crucial as we prepare for first efficacy readouts from our LIBERATE study and execute our strategy to build a truly world-class company.   Read the full press release: https://lnkd.in/efpcyuQ2   #tregs #Hepatology #Immunosuppression

We are delighted to announce that QEL-001, Quell Tx’s multi-modular engineered CAR-Treg cell therapy, is being advanced into the efficacy cohort of the LIBERATE Phase 1/2 trial in liver transplant patients. A trial progress update was presented today at the American Transplant Congress in Philadelphia, PA, USA.   We look forward to entering the next phase of this clinical trial, which has been designed to test a new, potentially transformational paradigm for liver transplant patients.   Find out more: https://lnkd.in/ekQeuEy4   #Immunosuppression #Hepatology #ATC2024

This week our team are in Vancouver for #ISCT2024. Our SVP Research & Product Development Nathalie Belmonte will be giving a presentation tomorrow (31st May) discussing how we are using CAR-Tregs to treat autoimmune diseases. Yesterday, Sim Tung presented a poster on our technology platform, and Aleks Guvenel, shared his insights on a panel re: next gen manufacturing platforms. Great to see our R&D team presenting our science to the global cell therapy community!

Our team are excited to be coming together with the Treg community this week at the 6th Annual Treg Summit in Boston. Our CMO Luke Devey will be joining a panel discussion today (May 22) and our VP Biology Marc Martinez-Llordella will be presenting an update on Quell’ scientific progress tomorrow (May 23). #CARTregs

Our team had a fantastic week at ASGCT conference in Baltimore - we had a great reception from the community to our CAR-TReg science, and came away with lots of new ideas to further build our platform forward to create transformative therapies for patients. Bravo!

We are looking forward to #ASGCT24 next week where our team will be presenting our progress on developing multi-modular engineered Treg cell therapies for patients with solid organ transplant and autoimmune diseases. Learn more about our upcoming oral and poster presentations here:

A big shout-out to Afrah Albadri and Maxim Smith for going above and beyond with our company values! We are very proud to have you here at Quell Tx.

We’re delighted to have received the European Lifestars Award for Deal of the Year (>$500M) last night, for our $2+ billion partnership with AstraZeneca to develop Treg cell therapies for Type 1 Diabetes and Inflammatory Bowel Disease.   This award recognises the transformational value of this deal for both the company and wider industry and wouldn't have been possible without the hard work and dedication of our team. Congratulations also to the AstraZeneca deal team who partnered with us to get this collaboration together.